Showing 4 posts of 4 posts found.

Xencor and UCLA TDG partner to develop therapeutic antibodies

February 25, 2021
Xencor, ucla

Xencor and UCLA Technology Development Group (UCLA TDG) have announced an agreement to develop novel therapeutic antibodies, pairing novel targets …

FDA halts Xencor’s acute myeloid leukaemia trial following two patient deaths

February 21, 2019
Research and Development Cancer, FDA, Xencor, leukaemia, pharma

Cancer biopharma firm Xencor has revealed it is to place a hold on its ongoing Phase 1 trial of XmAb14045, …


Novartis signs $150 million deal with Xencor to develop bispecific antibodies

June 28, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Cancer, Novartis, Xencor, bispecific antibodies, deal, drug development, drug trial

Swiss drugmaker Novartis (VTX: NOVN) said it has signed a $150 million upfront collaboration and licensing agreement with Xencor to …


Amgen joins M&A rush with deals for Dezima and Xencor

September 16, 2015
Research and Development, Sales and Marketing Amgen, Cancer, Denzime, Xencor, cardiovascular disease, high cholesterol, inflammation

Amgen has struck deals that could potentially be worth $3.25 billion, to purchase the Dutch firm Dezima and kick-off a …

Latest content